<PRE>
[Federal Register: March 13, 2002 (Volume 67, Number 49)]
[Notices]               
[Page 11356-11357]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr13mr02-122]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

 
Prospective Grant of Co-Exclusive License: Human Derived Monocyte 
Attracting Purified Peptide Products for Treating Human Infections and 
Neoplasms in a Human Body

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of a co-
exclusive license to practice the inventions embodied in the U.S. 
Patent Applications and issued Patents listed below to Centocor 
Corporation, having a place of business in Malvern, Pennsylvania. The 
patent rights of these inventions have been assigned to the United 
States of America.
    <bullet> USPA 07/330,446 filed March 30, 1989 and entitled ``Human 
Derived Monocyte Attracting Purified Peptide Products Useful in a 
Method of Treating Infections and Neoplasms in a Human Body and the 
Cloning of Full Length cDNA Thereof''
    <bullet> USPA 07/686,264 filed April 15, 1991 now USPN 6,090,795 
issued July 18, 2000
    <bullet> USPA 08/449,552 filed May 24, 1995 now USPN 5,532,144 
issued July 2, 1996
    <bullet> USPA 08/466,288 filed June 6, 1995 now USPN 5,714,578 
issued February 3, 1998
    <bullet> PCT/US90/00040 filed January 2, 1990
    The prospective co-exclusive license territory will be worldwide 
and the field of use may be limited to the treatment of asthma, 
restenosis, hepatitis B and cancer. This announcement serves as a 
modification of a notice previously published in the Federal Register, 
66 FR 59450-59451, Nov. 28, 2001.

DATES: Only written comments and/or license applications which are 
received by the National Institutes of Health on or before May 13, 
2002, will be considered.

ADDRESSES: Requests for copies of the patent, inquiries, comment and 
other materials relating to the contemplated co-exclusive license 
should be directed to: Percy S. Pan, Technology Licensing Specialist, 
Office of Technology Transfer, National Institutes of Health, 6011 
Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone

[[Page 11357]]

301-496-7736 x256; Facsimile 301-402-0220; e-mail <A HREF="mailto:panp@od.nih.gov">panp@od.nih.gov</A>.

SUPPLEMENTARY INFORMATION: The invention relates to a human derived 
purified peptide product that exhibits monocytic chemotactic activity 
(MCA). A method of preparing the peptide is disclosed as well as a 
method of treating neoplasms and infections by administering the 
peptides. A pharmaceutical composition of the peptide is also claimed. 
The peptide may be useful in the treatment of various disorders 
including autoimmune disease, chronic inflammatory diseases, and 
cancer. This peptide, also known as MCP-1, is a b chemokine. Chemokines 
are multipotent cytokines that localize and enhance inflammation by 
inducting chemotaxis and activation of different types of inflammatory 
cells. This peptide is a chemotactic factor for monocytes. It 
stimulates histamine release and regulates cytokine production in 
monocytes.
    The prospective co-exclusive license will be royalty-bearing and 
will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 
404.7. The prospective co-exclusive license may be granted unless 
within sixty (60) days from the date of this published notice, the NIH 
receives written evidence and argument that establish that the grant of 
the license would not be consistent with the requirements of 35 U.S.C. 
209 and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated co-exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and to the 
extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: March 7, 2002.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 02-6061 Filed 3-12-02; 8:45 am]
BILLING CODE 4140-01-P

</PRE>